- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00350480
Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial
Treatment of Non-Gestational Acute Uterine BleedingComparing Oral Medroxyprogesterone Acetate and Monophasic Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acute uterine bleeding, unrelated to pregnancy, is a relatively common problem that causes many reproductive-aged women to requite emergent medical and/or surgical intervention. Although the traditional approaches have generally been surgical in nature, many practitioners utilize medical methods to arrest the bleeding. However, despite widespread use, there exists a paucity of information regarding the effectiveness, side-effects, and patient satisfaction associated with the commonly-used medical regimens. (b) The purpose of the study is to compare the efficacy of multidose medroxyprogesterone acetate and a multidose, monophasic combined oral contraceptive in the treatment of hemodvnamically-stable women with non-gestational, acute uterine bleeding.
(c) Non-pregnant, hemodynamically-stable, reproductive-aged, women, over the age of IS, who present either to the emergency area or to KP practitioner's offices with acute uterine bleeding, will be considered for eligibility. If, following a full exam and medically appropriate investigations medical management is deemed appropriate, they will be approached by a member of the investigating team for possible inclusion into the study. Following informed consent, patients will be randomized to receive either medroxyprogesterone acetate (20 mg three times daily for 7 days) or monophasic oral contraceptive containing I mg of norethindrone and 35 ug of ethinyl estradiol (three dines daily for seven days). Following the seven days of therapy, those randomized to MPA will continue with 20 mg per day for three weeks while those randomized to oral contraceptives will take one pill per day for three weeks, each completing a total of four weeks of therapy. The primary outcome will be the number of days until cessation of bleeding. Other outcomes measured will include pad and tampon counts, and hemoglobin levels. Chi square tests and student t will be used to evaluate differences between the two treatment groups. The hope is that this study will elucidate on the efficacy of the two regimens.
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Kaiser Permanente Sunset
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Non-pregnant Hemodynamically stable Reproductive-aged women >18 years Present with acute uterine bleeding
Exclusion Criteria:
Pregnant Non-hemodynamically stable <18 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The avoidance of unscheduled surgery in the 28-day follow-up period.
|
To calculate the time requred from initiation of medical therapy until the cessation bleeding, comparing MPA to monophasic combination oral contraceptive pills.
|
Secondary Outcome Measures
Outcome Measure |
---|
The assessment of pad and tampon counts.
|
The assessment of hemoglobin levels, symptoms and side effects (ie: cramping, nausea and bloating) and patient satifaction with medical therapy.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Malcolm G Munro, M.D., Southern California Permanente Medical Group
- Principal Investigator: Romie Basu, MD, Southern California Permanente Medical Group
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Uterine Diseases
- Menstruation Disturbances
- Hemorrhage
- Menorrhagia
- Uterine Hemorrhage
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Contraceptive Agents, Male
- Contraceptives, Oral
- Contraceptives, Oral, Combined
- Medroxyprogesterone Acetate
Other Study ID Numbers
- Uterine Bleeding
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Hemorrhage
-
Maxima Medical CenterUtrecht UniversityActive, not recruiting
-
The Cleveland ClinicCompletedAbnormal Uterine BleedingUnited States
-
Female Pelvic Medicine & Urogynecology Institute...Ethicon, Inc.Completed
-
Laval UniversityCompletedUterine Atony | Post-partum HemorrhageCanada
-
Glenveigh MedicalTerminatedPostpartum Uterine BleedingUnited States
-
University of Texas Southwestern Medical CenterWithdrawnAdenomyosis | Abnormal Uterine Bleeding
-
Sisli Hamidiye Etfal Training and Research HospitalCompletedAbnormal Uterine Bleeding
-
Chulalongkorn UniversityUnknown
-
Raydiant Oximetry, Inc.Not yet recruitingCesarean Section Complications | Post Partum Hemorrhage | Uterine Bleeding | Uterine Atony With Hemorrhage
-
University of California, DavisWashington University School of MedicineTerminatedUterine Bleeding Heavy | Abnormal Uterine Bleeding, UnspecifiedUnited States
Clinical Trials on Provera
-
FHI 360Completed
-
University Hospital of North NorwayNorwegian Cancer Society; Helse NordCompletedEndometrial HyperplasiaNorway
-
FHI 360Oregon Health and Science University; Asociación Dominicana Pro Bienestar de...CompletedContraceptionUnited States, Dominican Republic
-
Women's Health Care Clinic, Torrance, CaliforniaCompletedDysfunctional Uterine BleedingUnited States
-
National Cancer Institute (NCI)CompletedEndometrial CancerUnited States
-
Guy WaddellCSSS ChicoutimiTerminated
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS)Recruiting
-
Oregon Health and Science UniversityRecruiting
-
Massachusetts General HospitalThe Hospital for Sick Children; National Institute of Diabetes and Digestive...Completed
-
Boston UniversityFamily Planning FellowshipCompletedAbortion; InducedUnited States